Pmvch - Freepik.com
Next Edition in April 2027
adline e D g n i Book 2027 h c r a 31 M
Reserve your company profile now!
The Voice of Europe‘s Biotech Industry! The “17th European Biotechnology Science & Industry Guide 2027” – the handbook that presents the strengths and core competencies of companies and institutions in the fields of Biotech, Biopharma, BioServices and BioManufacturing in Europe. Besides the printed version the guide will also be available as a digital version.
International Distribution Print & Digital!
ate D n o i t a Public 27 0 2 l i r p 22 A
17th European Biotechnology Science & Industry Guide 2027 Publication date: April 22, 2027 Print run 10,000 copies digital circulation to 45,000 recipients In cooperation with European biotech clusters & regions Distribution at events throughout the year (planned): ∙ Swiss Biotech Day 2027, Basel (CH) ∙ Life Science Baltics 2027, Kaunas (LT) ∙ SLAS Europe 2027, Hamburg (D) ∙ UK Biotech Day, London (UK) ∙ CDMO Live Europe, Rotterdam (NL) ∙ Chemspec Europe 2027, Basel (CH) ∙ Achema 2027, Frankfurt (D) ∙ bio:cap 2027, Berlin (D) ∙ BioSpain 2027, Barcelona (E) ∙ Biotech Austria Summit 2027, Graz (A) ∙ CPHI 2027, Frankfurt (D) ∙ BIO-Europe 2027, Stockholm (S) ∙ PharmaLab Congress 2027, Darmstadt (D) ∙ BioFIT 2027, Lille (F) ∙ and many more
also in s e l fi o r All p sion! r e v l a t i the dig
Address/P.O. Box › Manfred Eigen Campus Essener Bogen 7 Postal Code/City › 22419 Hamburg Country › Germany Contact Person › Sarah Fakih (EVP Head of Global Communications & Investor Relations) Telephone › +49-40-560810 Email › info@evotec.com Website › www.evotec.com Social Media › I Number of Employees › >4,800 Founded (year) › 1993 Areas of Activity › Drug discovery & preclinical development; integrated R&D services; small molecules & biologics; cell therapies; AI-driven discovery; PanOmics & iPSC-based disease modeling; ADME-Tox(Cyprotex); biologics development & manufacturing (Just – Evotec Biologics); oncology; neuroscience/CNS; metabolic & cardiovascular diseases; immunology; infectious diseases. Annual turnover › € 797.0 m (2024) Relevant R&D budget › € 50.8 m (2024) Biological Patents › A broad portfolio of patent families relating to compounds, targets, and assays. External › Evotec is working with more than 800 Collaborations pharma and biotech companies, academic institutions, and healthcare stakeholders globally. Request for › Our sales teams are happy to discuss Further Collaborations our end-to-end R&D solutions, in- and out-licensing opportunities, and how we can assist you in meeting your drug discovery and preclinical development needs.
Evotec is a globally operating life science company advancing drug discovery, preclinical development, and manufacturing through highly integrated, technologyenabled partnerships. Headquartered in Hamburg, Germany, Evotec delivers comprehensive solutions that translate deep molecular disease understanding into innovative, high-quality therapeutics across multiple modalities. Evotec’s activities cover the full continuum from target identification to clinical and commercial manufacturing, enabling flexible collaboration models for pharmaceutical, biotechnology, academic, and non-profit partners worldwide. By combining advanced science, leading technologies, and data-driven innovation, Evotec accelerates the discovery and preclinical development of differentiated medicines across a broad range of therapeutic areas. The company’s partnership approach goes beyond traditional service delivery by offering access to proprietary platforms, extensive multimodal data resources, and shared scientific risk and reward.
Discovery & Preclinical Development A core strategic pillar of Evotec’s business is its Discovery & Preclinical Development (D&PD) segment, which integrates biological expertise with proprietary technology platforms to make early-stage R&D more predictive and effective. At the intersection of science, technology, and data, Evotec applies industrialised, multimodal approaches to understand disease biology and translate insights into high-quality development candidates. Key capabilities include the PanOmics multi-omics platform, extensive molecular patient databases, and iPSC-based disease modelling, enabling highly translational, patient-relevant research across diverse indications.
A defining feature of D&PD is the integration of AI and machine learning throughout discovery workflows. Scalable data infrastructures, advanced analytics, and AI-enabled models support faster hypothesis generation and validation, deeper target characterisation, and smarter compound and modality design. By systematically linking biological data with predictive algorithms, Evotec enhances decision-making, reduces attrition risk, and improves the probability of clinical success.
Digital Edition
Just – Evotec Biologics Evotec’s second strategic pillar, Just – Evotec Biologics, extends the company’s capabilities into the design, preclinical development, and manufacturing of biologics. Built on the proprietary J.DESIGN platform, it combines molecular optimisation, process development, and continuous bioprocessing to deliver efficient, scalable, and flexible production of modern biotherapeutics. This advanced manufacturing approach is designed to reduce scale-up risk, shorten timelines, and improve cost efficiency while maintaining the highest quality standards, supporting both innovative biologics and next-generation modalities. Through the combination of integrated discovery platforms, strong AI-enabled analytics, and next-generation biologics manufacturing, Evotec positions itself as a long-term innovation partner committed to improving efficiency, predictability, and success rates of drug development to bring new therapies to patients faster.
Member of 16 TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 60 60
| 61
he digital version of the guide containing T all profiles will be available via download for 45,000+ newsletter subscribers of european-biotechnology.com and www.transkript.de.
Picture: www.istockphoto.com/pressureUA
EVOTEC
Name › Evotec SE
1-Page Start-up Profile
RIANA THERAPEUTICS
Name › RIANA Therapeutics Address/P.O. Box › Veterinaerplatz 1
Email › office@rianatx.com Website › www.rianatx.com Social Media › I Number of Employees › 5 Founded (year) › 2023 Areas of Activity › | Oncology therapeutics | Acute myeloid leukaemia (AML) | Protein-protein interaction inhibitors | STAT5 signalling & transcription factors | Small-molecule drug discovery | Precision oncology
© Thomas Suchanek
Postal Code/City › 1210 Vienna Country › Austria Contact Person › Anna Orlova, PhD
Patient-centred innovation targeting STAT5 to overcome AML resistance RIANA Therapeutics is a female-led, Vienna-based biotech startup developing first-in-class small molecule therapies for patients with acute myeloid leukemia (AML) and other STAT5-driven cancers. Our mission is to address urgent unmet needs by targeting mechanisms that current treatments fail to control, including FLT3positive AML, where relapse rates remain high despite targeted therapies. RIANA focuses on STAT5, a key driver of disease progression and therapy resistance in AML. Although STAT5 is a central resistance node, it has long been considered undruggable due to challenging protein–protein interaction interfaces. Our approach selectively disrupts STAT5 oligomerization, which is essential for its oncogenic activity, while preserving physiological function. By targeting resistance at its molecular root, we aim to complement existing therapies such as FLT3 and BCL-2 inhibitors and improve patient outcomes. With a lean structure and strong external expertise, RIANA is advancing from validated hits toward lead identification and preclinical development, preparing for its first seed round in 2026. 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 138
Prices: 2-Page Company Profile 1,580 € standard rate 1,264 € reduced rate for previous participants and members of our publication partners
1-Page Start-up Profile 990 € for firms less than 5 year and less than 20 employees
Services: company article (1- or 2-pager) with text, images and logo inclusive: layout, proof reading, and free copies of the book (max 10 copies) implementation of your company profile from the pirinted guide into the digitale version
Optional: Reprints/Leaflets of your profile 1,000 reprints (4-colored) of your company profile for about 480 € net.
Contact: Andreas Macht | Email: andreas.macht@knowb.io | Tel. +49 30 2649 2154
| 139
Mock-Ups: kenoric/graphicriver.net
Member of
Reservation Form for 2027 Edition PLEASE MAKE YOUR SELECTION We order our company presentation in the “17th European Biotechnology Science & Industry Guide 2027” for the net price of 1,580 € (990 € for start ups only). This includes layout, proof reading, up to 10 free copies of the book, and implementation into the digtial book version. Number of free voucher copies: ...... (max. 10) We are entitled to 20% discount on the standard rate for the 2-pager profile because we were already represented in former guide editions or as member of a partner association of the guide. Additionally to our guide presentation we wish to order 1,000 extra reprints as a four-colour flyer for the net price of 480 €. Questions? Please call +49 (0)30-264921-54 This order can be revoked within 10 days.
Company/Institution ·
..........................................................................
Name ·
..........................................................................
Address/P.O. Box ·
..........................................................................
Postal Code/City ·
..........................................................................
Country ·
..........................................................................
Telephone ·
..........................................................................
Fax ·
..........................................................................
Email ·
..........................................................................
Date ·
..........................................................................
Signature ·
..........................................................................
Stamp ·
..........................................................................
Email: andreas.macht@knowb.io
Knowbio GmbH Lessingstr. 12 16552 Schildow bei Berlin | Germany